[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.239.151.158. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
March 1962

Use of Edmonston Attenuated Measles Strain: A Summary of Three Years' Experience

Author Affiliations

BOSTON
Samuel L. Katz, M.D., The Children's Hospital Medical Center, Boston.; From the Research Division of Infectious Diseases, The Children's Hospital Medical Center, and the Departments of Pediatrics and Bacteriology and Immunology, Harvard Medical School.; Chief, Newborn Division and Research Associate, ate, Research Division of Infectious Diseases, The Children's Hospital Medical Center, and Associate in Pediatrics, Harvard Medical School (Dr. Katz); Chief, Research Division of Infectious Diseases, The Children's Hospital Medical Center, and Professor of Bacteriology and Immunology at the Children's Hospital, Harvard Medical School (Dr. Enders).

Am J Dis Child. 1962;103(3):340-344. doi:10.1001/archpedi.1962.02080020352031
Abstract

Introduction  Three years have elapsed since the first trial in susceptible children of an attenuated measles virus propagated in tissue cultures of chick embryo cells.1 During this period of time it has been possible to enlarge our experience with the administration of vaccine to both normal children and those suffering from various disorders, to accumulate further data documenting the clinical and serological responses induced by this material, and to observe the prophylactic efficacy of vaccination in varying environmental situations. The initial study, undertaken in 1958, included only 13 residents of a state institution for the mentally deficient. More than 10,000 children have now received similar vaccine in one fashion or another. In addition to healthy children and a few adults, those vaccinated include individuals with tuberculosis, asthma, cystic fibrosis, rheumatoid arthritis, cerebral palsy, epilepsy, malnutrition, nephrosis, cardiac disease, adrenocortical hyperplasia, nephrogenic diabetes insipidus, phenylketonuria, sickle-cell trait, and leukemia. The age of vaccine

×